ACHL

Achilles Therapeutics plc

1.33 USD
+0.10 (+8.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Achilles Therapeutics plc stock is up 47.78% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 February’s closed higher than January.

About Achilles Therapeutics plc

Achilles Therapeutics Plc develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; THETIS, a product candidate in clinical trials for use of metastatic or recurrent melanoma. Achilles is headquartered in London, the United Kingdom.